Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has maintained a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased the price target from $70 to $77.
March 05, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Vamil Divan reaffirmed a Buy rating on ANI Pharmaceuticals and raised the price target from $70 to $77.
The upgrade in price target by a reputable analyst like Vamil Divan from Guggenheim signals a strong confidence in ANI Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in ANIP's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100